OCUGEN, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
OCUGEN, INC. (OCGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.01 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-06
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-06-30 was $1.01, a 27.85% increase year-over-year.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $1.20, a 60.00% increase year-over-year.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-09-30 was $0.91, a 23.53% decline year-over-year.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was $0.79, a 37.80% decline year-over-year.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $0.81, a 1.25% increase from fiscal 2024.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $0.80, a 5.88% decline from fiscal 2023.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $0.85, a 72.76% decline from fiscal 2022.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $3.12, a 8.71% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $1.01 10-Q · filed 2026-08-06 | $1.17 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $1.20 10-Q · filed 2026-05-08 | ||||
| 2025-12-31 | $0.81 10-K · filed 2026-03-04 | ||||
| 2025-09-30 | $0.91 10-Q · filed 2025-11-05 | $0.79 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $0.79 10-Q · filed 2026-08-06 | $0.76 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $0.75 10-Q · filed 2026-05-08 | ||||
| 2024-12-31 | $0.80 10-K · filed 2026-03-04 | ||||
| 2024-09-30 | $1.19 10-Q · filed 2025-11-05 | $0.81 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $1.27 10-Q · filed 2025-08-04 | $0.77 10-Q · filed 2025-08-04 | |||
| 2024-03-31 | $0.58 10-Q · filed 2025-05-09 | ||||
| 2023-12-31 | $0.85 10-K · filed 2025-03-05 | ||||
| 2023-09-30 | $0.41 10-Q · filed 2024-11-14 | $0.87 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $0.43 10-Q · filed 2024-08-08 | $0.88 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $1.01 10-Q · filed 2024-05-14 | ||||
| 2022-12-31 | $3.12 10-K · filed 2024-04-16 | ||||
| 2022-09-30 | $2.01 10-Q · filed 2023-11-09 | $3.19 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $1.96 10-Q · filed 2023-08-21 | $3.26 10-Q · filed 2023-08-21 | |||
| 2022-03-31 | $3.61 10-Q · filed 2023-05-05 | ||||
| 2021-12-31 | $2.87 10-K · filed 2023-02-28 | ||||
| 2021-09-30 | $5.97 10-Q · filed 2022-11-08 | $2.77 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | $4.98 10-Q · filed 2022-08-05 | $2.60 10-Q · filed 2022-08-05 | |||
| 2021-03-31 | $1.73 10-Q · filed 2022-05-06 | ||||
| 2020-12-31 | $0.34 10-K · filed 2022-02-28 | ||||
| 2020-09-30 | $0.34 10-Q · filed 2021-11-09 | $0.34 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | $0.28 10-Q · filed 2021-08-06 | $0.34 10-Q · filed 2021-08-06 | |||
| 2020-03-31 | $0.42 10-Q · filed 2021-05-07 | ||||
| 2019-12-31 | $0.84 10-K · filed 2022-02-28 | ||||
| 2018-12-31 | $7.97 10-K · filed 2020-03-27 | $0.59 10-K · filed 2019-03-22 | |||
| 2018-09-30 | $1.06 10-Q · filed 2018-11-08 | $1.77 10-Q · filed 2018-11-08 | |||
| 2018-06-30 | $1.67 10-Q · filed 2018-08-09 | $1.91 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | $1.96 10-Q · filed 2018-05-10 | ||||
| 2017-12-31 | $1.02 10-K · filed 2019-03-22 | ||||
| 2017-09-30 | $1.14 10-Q · filed 2018-11-08 | $1.01 10-Q · filed 2018-11-08 | |||
| 2017-06-30 | $0.96 10-Q · filed 2018-08-09 | $1.01 10-Q · filed 2018-08-09 | |||
| 2017-03-31 | $1.04 10-Q · filed 2018-05-10 | ||||
| 2016-12-31 | $1.26 10-K · filed 2018-03-15 | ||||
| 2016-09-30 | $2.47 10-Q · filed 2017-11-09 | $1.40 10-Q · filed 2017-11-09 | |||
| 2016-06-30 | $1.07 10-Q · filed 2017-08-10 | $1.42 10-Q · filed 2017-08-10 | |||
| 2016-03-31 | $1.43 10-Q · filed 2016-05-12 | ||||
| 2015-12-31 | $4.08 10-K · filed 2017-03-16 | ||||
| 2015-09-30 | $3.22 10-Q · filed 2016-11-10 | $4.55 10-Q · filed 2016-11-10 | |||
| 2015-06-30 | $3.88 10-Q · filed 2016-08-11 | $5.48 10-Q · filed 2016-08-11 | |||
| 2015-03-31 | $4.51 10-Q · filed 2016-05-12 | ||||
| 2014-12-31 | $6.70 10-K · filed 2016-03-10 | ||||
| 2014-09-30 | $7.29 10-Q · filed 2015-11-12 | $6.74 10-Q · filed 2015-11-12 | |||
| 2014-06-30 | $6.50 10-Q · filed 2015-08-12 | $6.50 10-Q · filed 2015-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |